Featured Slider

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for January 2024.

EAN President Paul Boon takes a look at some of the major EAN events of 2023 and casts an eye over what is to come in 2024, when we will celebrate ten years of the EAN.

This study presents the results of a clinical trial investigating whether apixaban, compared to aspirin, would be associated with reduced risk of stroke or systemic embolism, with a tolerably low risk of major bleeding.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for December 2023.

EAN Secretary General, Tony Marson, provides an update on the benefits of EAN membership, as well as some key dates and events on the horizon for members.

Our Paper of the Month for November is a meta-analysis investigating the safety and efficacy of oral anticoagulation for prevention of major cardiovascular events in patients with atrial fibrillation and previous spontaneous intracranial haemorrhage.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for November 2023.

EAN President, Paul Boon, provides an update on recent and forthcoming events, including brain health activities in the US, the EAN Brain Health Summit on 16 November, and the National Neurological Societies Forum.

Our Paper of the Month for October 2023 is a multicentre, prospective, randomised clinical trial investigating whether transdermal nicotine may have a disease-modifying effect in early, therapy-naïve Parkinson's disease.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for October 2023.

EAN Scientific Committee Chair, Thomas Berger on the forthcoming Mangement Group elections, new guidelines, and the EAN's readiness to support EU Horizon applications.

Our paper of the month presents the results of a randomised trial assessing AXER-204, a soluble decoy fragment of NgR1 able to block the action of three inhibitors of the axonal growth in individuals with chronic traumatic cervical SCI.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for September 2023.

EAN President Paul Boon looks back at the 9th Congress of the European Academy of Neurology, which took place in Budapest on 1-4- July.

Our paper of the month is a phase 3, double-blind, multicentre, trial investigating the efficacy and the safety of vorasidenib, a dual inhibitor of the IDH1 and IHD2 enzymes, in patients with residual or recurrent IDH mutant grade 2 gliomas.